Study of Predictive Factors of Chemoresistance in Ovarian Cancer
Completed
- Conditions
- Ovarian Cancer
- Interventions
- Procedure: Cancer treatment
- Registration Number
- NCT02878122
- Lead Sponsor
- Rennes University Hospital
- Brief Summary
Epithelial ovarian cancer (EOC) has a poor prognosis. EOC management requires debulking surgery and chemotherapy based on taxol and carboplatine. Initial response is often good, but most often a recurrence occurred in the first 18 months. Early recurrence signs chemoresistance and palliative treatment. The study of predictive clinical or biological factors is required to adapt therapeutic and develop new treatments.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 13
Inclusion Criteria
- patient > 18 years of age
- patient with histological proven epithelial ovarian cancer
Exclusion Criteria
- patients who can not give their own consent
- patients without ovarian cancer
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients with epithelial ovarian cancer Cancer treatment Cancer treatment
- Primary Outcome Measures
Name Time Method Chemoresistance defined by clinical recurrence 6 months after the end of chemotherapy Chemoresistance defined by biological recurrence 6 months after the end of chemotherapy Chemoresistance defined by radiological recurrence 6 months after the end of chemotherapy
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
LAVOUE
🇫🇷Rennes, France